STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway

Yin, Mingming; Hu, Jinlong; Zhou, Yuan; Luo, Guangyi; Yao, Jiaming; Wang, Rundong; Liu, Dongquan; Cao, Baoqiang; Wu, Wenyong; Hu, Zhiqi

doi:10.1080/15384101.2022.2029996

Cited by 18 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, EMT can be inhibited by Wnt/beta-catenin pathway, thereby inhibiting cancer cell metastasis [ 56 ]. It has been demonstrated that STING agonists can inhibit the growth and proliferation of breast cancer cells and can be used not only in the treatment of breast cancer, but also in combination with atenrizumab to enhance the efficacy of immunotherapy [ 57 ]. However, persistent overactivation of STING induces chronic inflammation and involves a wide range of autoimmune diseases [ 38 , 41 ], and whether its activation induces a negative feedback loop that inhibit the action of STING agonists remains to be further investigated.…”

Section: Discussionmentioning

confidence: 99%

Bibliometric and Visualized Analysis of the Current Status on STING Signaling Pathway and Cancer

Sui

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Cancer, as the second leading cause of death worldwide, has become an ongoing public health challenge and its treatment has received much attention, with immunotherapy becoming a hot research topic in recent years. The interferon gene stimulating factor (STING)-mediated signaling pathway has a “double-edged sword” role in cancer, which plays different roles in different types and stages of tumors. In this paper, we discuss the current research status, cooperation, and hotspots of STING signaling pathway in cancer from 2008–2022 using CiteSpace software based on the literature of cancer and STING signaling pathway. In addition, we predicted future research trends in this field by analysis, and the results showed that the STING signaling pathway is rapidly increasing in cancer research, and its role in tumor microenvironment and immunotherapy has become a new hot spot in current research and will continue to receive high attention.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric and Visualized Analysis of the Current Status on STING Signaling Pathway and Cancer

Sui

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…As a mechanism of stimulating STING in immune cold tumors, either 2′3′-cGAMP or agonists (small molecules that activate STING) have been implemented to stimulate interferon expression and promote an anti-tumor immune response (Deng et al, 2014). Using the 4T1 TNBC model, the STING agonist, cyclic diguanylate, lead to induction of IFNβ expression which was coupled to an increase in activation of STING and its downstream effectors (Yin et al, 2022). Cyclic diguanylate synergized with atezolizumab (anti-PDL1) to reduce tumor growth through activation of cytotoxic T-cells and suppression of T regs (Yin et al, 2022).…”

Section: Induction Of Ifn Expression Through Sustaining Sting Activationmentioning

confidence: 99%

“…Using the 4T1 TNBC model, the STING agonist, cyclic diguanylate, lead to induction of IFNβ expression which was coupled to an increase in activation of STING and its downstream effectors (Yin et al, 2022). Cyclic diguanylate synergized with atezolizumab (anti-PDL1) to reduce tumor growth through activation of cytotoxic T-cells and suppression of T regs (Yin et al, 2022). Other work on a HER2+ model using the STING activator, ADU-S100, demonstrated that STING activation can induce tumor regression as well as protect against tumor rechallenge in nontolerized animals (Foote et al, 2017).…”

Section: Induction Of Ifn Expression Through Sustaining Sting Activationmentioning

confidence: 99%

Tailoring therapies to counter the divergent immune landscapes of breast cancer

Attalla

Taifour²,

Muller³

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Breast cancer remains a significant clinical concern affecting millions of women worldwide. Immunotherapy is a rapidly growing drug class that has revolutionized cancer treatment but remains marginally successful in breast cancer. The success of immunotherapy is dependent on the baseline immune responses as well as removing the brakes off pre-existing anti-tumor immunity. In this review, we summarize the different types of immune microenvironment observed in breast cancer as well as provide approaches to target these different immune subtypes. Such approaches have demonstrated pre-clinical success and are currently under clinical evaluation. The impact of combination of these approaches with already approved chemotherapies and immunotherapies may improve patient outcome and survival.

show abstract

“…STING agonists exhibited effective antitumor activity, including cyclic di-guanosine monophosphate and synthetic cyclic dinucleotide derivatives [ 106 ]. A number of studies demonstrated that STING agonists combined with a cancer vaccine or delivery platform induced a potent inflammatory response and modulated the tumor microenvironment by increasing proliferation of CD4+ T cell [ 107 , 108 , 109 , 110 ]. Although STING agonists might cause some systemic toxicity, the novel strategies of combined therapy would accelerate their application as a cancer vaccine adjuvant.…”

Section: Adjuvantsmentioning

confidence: 99%

Recent Advances in DNA Vaccines against Lung Cancer: A Mini Review

Huang

Liu²,

et al. 2022

Vaccines

View full text Add to dashboard Cite

Lung cancer is regarded as the major causes of patient death around the world. Although the novel tumor immunotherapy has made great progress in the past decades, such as utilizing immune checkpoint inhibitors or oncolytic viruses, the overall 5-year survival of patients with lung cancers is still low. Thus, development of effective vaccines to treat lung cancer is urgently required. In this regard, DNA vaccines are now considered as a promising immunotherapy strategy to activate the host immune system against lung cancer. DNA vaccines are able to induce both effective humoral and cellular immune responses, and they possess several potential advantages such as greater stability, higher safety, and being easier to manufacture compared to conventional vaccination. In the present review, we provide a global overview of the mechanism of cancer DNA vaccines and summarize the innovative neoantigens, delivery platforms, and adjuvants in lung cancer that have been investigated or approved. Importantly, we highlight the recent advance of clinical studies in the field of lung cancer DNA vaccine, focusing on their safety and efficacy, which might accelerate the personalized design of DNA vaccine against lung cancer.

show abstract

STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway

Cited by 18 publications

References 43 publications

Bibliometric and Visualized Analysis of the Current Status on STING Signaling Pathway and Cancer

Bibliometric and Visualized Analysis of the Current Status on STING Signaling Pathway and Cancer

Tailoring therapies to counter the divergent immune landscapes of breast cancer

Recent Advances in DNA Vaccines against Lung Cancer: A Mini Review

Contact Info

Product

Resources

About